Ohcanbohtosat - Fleming, Thomas R

Identifying and Addressing Safety Signals in Clinical Trials Dahkki Fleming, Thomas R.

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

Addressing Missing Data in Clinical Trials Dahkki Fleming, Thomas R.

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

Clinical Trials: Discerning Hype From Substance Dahkki Fleming, Thomas R.

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

Protecting the Confidentiality of Interim Data: Addressing Current Challenges Dahkki Fleming, Thomas R.

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

Evaluating interventions for Ebola: The need for randomized trials Dahkki Fleming, Thomas R, Ellenberg, Susan S

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

Issues in Noninferiority Trials: The Evidence in Community-Acquired Pneumonia Dahkki Fleming, Thomas R., Powers, John H.

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

Biomarkers and Surrogate Endpoints In Clinical Trials Dahkki Fleming, Thomas R., Powers, John H

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

Adjusting for unknown bias in non-inferiority clinical trials Dahkki Odem-Davis, Katherine, Fleming, Thomas R.

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

Noninferiority trials: clinical understandings and misunderstandings Dahkki Powers, John H, Fleming, Thomas R

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

Cardiovascular Safety Trials of Antidiabetic Therapies to Treat Type 2 Diabetes: Perhaps Asking the Wrong Question? Dahkki Psaty, Bruce M, Fleming, Thomas R

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

Achieving effective informed oversight by DMCs in COVID clinical trials Dahkki DeMets, David L., Fleming, Thomas R.

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

Executive Summary: Workshop on Issues in the Design and Conduct of Clinical Trials of Antibacterial Drugs in the Treatment of Community-Acquired Pneumonia Dahkki Spellberg, Brad, Fleming, Thomas R., Gilbert, David N.

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

Challenges in the Design of HIV Prevention Trials in the United States Dahkki Donnell, Deborah, Hughes, James P., Fleming, Thomas R.

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

Designing & Conducting Trials To Reliably Evaluate HIV Prevention Interventions Dahkki Fleming, Thomas R., DeGruttola, Victor, Donnell, Deborah

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

Issues in Using Progression-Free Survival When Evaluating Oncology Products Dahkki Fleming, Thomas R., Rothmann, Mark D., Lu, Hong Laura

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

Chemosensory Responses of Plant Parasitic Nematodes to Selected Phytochemicals Reveal Long-Term Habituation Traits Dahkki Fleming, Thomas R., Maule, Aaron G., Fleming, Colin C.

Viečča ollesdeavstta Viečča ollesdeavstta

Data Monitoring Committees: Current Issues Dahkki Fleming, Thomas R, Ellenberg, Susan S, DeMets, David L

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

Monitoring clinical trials in infectious diseases Dahkki DeMets, David L, Fleming, Thomas R, Ellenberg, Susan S

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

Discussion: The role, position, and function of the FDA—The past, present, and future Dahkki Fleming, Thomas R., Demets, David L., McShane, Lisa M.

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

Testing in a Prespecified Subgroup and the Intent-to-Treat Population Dahkki Rothmann, Mark D., Zhang, Jenny J., Lu, Laura, Fleming, Thomas R.

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta